癌症生物标记市场:目前分析与预测(2022-2030年)

癌症生物标誌物是癌细胞和人体组织响应癌症而产生的生物分子。近年来，癌症生物标誌物在癌症的早期检测和个性化药物的开发中受到了广泛的关注。随着癌症患病率的激增，全球癌症生物标誌物市场也在不断增长。根据国际癌症研究机构（IARC）的报告《GLOBOCAN》，2020年全球将新增约1930万癌症患者，约1000万癌症相关死亡。我来了。IARC 估计，2020 年至 2040 年间，全球新发癌症病例将增加 47%。

为了更好地了解癌症生物标誌物行业的市场实施情况，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区）、亚洲太平洋地区（中国、日本、印度、亚太地区其他地区）和世界其他地区。2021年，北美将主导市场。这一增长的主要驱动力是先进技术的高采用率、癌症患病率的激增以及调查数量的增加。例如，2023 年 5 月，Culmination Bio 将与 Cofactor Genomics 合作，利用来自美国最大生物库之一的样本和数据，加速 Cofactor Genomics 的 OncoPrism(TM) 测试在 11 种癌症中的开发。此次合作的目的是建立癌症生物标誌物，这些标誌物正在国内临床试验 PREDAPT（通过治疗前肿瘤活检分析预测免疫治疗效果）中进行研究。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提

• 调查流程
• 调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 全球癌症生物标记市场上新型冠状病毒感染疾病(COVID-19)的影响

第6章 全球癌症生物标记的市场收益，2020-2030年

第7章 市场洞察:各类型

• 蛋白质
• 遗传的生物标记
• 糖锁链生物标记

第8章 市场洞察:各适应症

• 前列腺癌症
• 乳癌
• 肺癌症
• 结肠直肠癌症
• 子宫颈癌症
• 胃癌
• 肝臟癌症
• 其他

第9章 市场洞察:分析各技术

• 组学技术
• 成像技术
• 免疫学的检验
• 生物资讯学
• 细胞遗传学

第10章 市场洞察:各用途

• 药物研发与开发
• 诊断
• 预后
• 其他

第11章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第12章 癌症生物标记市场动态

• 推动市场要素
• 市场课题
• 影响分析

第13章 癌症生物标记市场机会

第14章 癌症生物标记市场趋势

第15章 需求面和供给面的分析

• 需求面分析
• 供给面分析

第16章 价值链分析

第17章 价格分析

第18章 竞争模式

• 波特的五力分析
• 竞争情形

第19章 企业简介

• Qiagen
• Abbott Laboratories Inc.
• Agilent Technologies
• Merck Millipore
• Biomerieux
• Quest Diagnostics
• F. Hoffmann-La Roche Ltd
• Hologic Inc.
• Illumina Inc.
• Thermo Fisher Scientific

第20章 免责声明

Cancer biomarkers are biological molecules that are produced either by tumor cells or human tissues in response to cancer. In the last few years, cancer biomarkers have gained considerable momentum for the early detection of cancer and the development of personalized medicines. The global cancer biomarker market is growing with the surge in the prevalence of cancer. According to the International Agency for Research on Cancer (IARC), in its report GLOBOCAN, has stated that approximately 19.3 million new cancer cases and about 10 million deaths related to cancer were recorded in 2020, across the globe. The IARC has estimated that new cancer cases are expected to rise by 47% all over the globe from 2020 to 2040.

The Cancer Biomarker Market is expected to grow at a strong CAGR of 13% during the forecast period owing to the rising pharmaceutical investment. For instance, in December 2020, US Food and Drug Administration (FDA) approved next-generation sequencing-based companion diagnostic for EGFR Exon 20 insertion mutant non-small cell lung cancer tumor tissue by Thermo Fisher Scientific. Further, in April 2021, F. Hoffmann-La Roche Ltd. released the Elecsys Anti-p53 immunoassay to aid in the diagnosis of various cancer kinds.

Based on the type, the market is segmented into protein, genetic biomarker, and glycol-biomarkers. The genetic biomarkers held a dominant share of the market in 2021 as they are utilized on a large scale and are very effective. These biomarkers are exclusively utilized for managing and diagnosing cancer, thus driving segmental growth.

By indication, the market is segmented into prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, stomach cancer, liver cancer, and others. The lung cancer segment is anticipated to grow with a significant CAGR during the forecast period. It is mainly attributed to the surge in the incidences of lung cancer and the associated rise in research and development activities. For instance, in February 2023, researchers at AIIMS created e-Nose for the detection of lung cancer. Further, in October 2020, RIKEN, iProgen Biotech Inc., and iPrime Therapeutics Co., entered into a collaboration to identify biomarkers unique to lung cancer cells suitable for targeted therapeutics.

Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, bioinformatics, and cytogenetics. The omics held a significant share of the market in 2021. Omics technology is highly effective in the early diagnosis of cancer. Furthermore, novel development in profiling technologies for cancer biomarkers is also having a positive impact on the growth of the market.

Based on application, the market is segmented into drug discovery & development, diagnostics, prognostics, and others. The drug discovery & development is expected to grow with significant CAGR during the forecast period. The segment is growing due to the growing awareness among healthcare practitioners about cancer biomarkers. In addition, the demand for personalized medicines is also growing. One of the key factors driving the segment growth is approvals on diagnostic tests are quite easy nowadays which is creating demand for cancer biomarkers.

For a better understanding of the market adoption of the cancer biomarker industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share of the market in 2021. The growth is mainly attributed to the higher adoption of advanced technologies, the surge in the prevalence of cancer, and the rise in the number of research studies. For instance, in May 2023, Culmination Bio entered into collaboration with Cofactor Genomics to leverage samples and data from one of the largest biobanks in the country to fuel the development of Cofactor Genomic's OncoPrism™ test in 11 cancers. The objective of the partnership is to build biomarkers for cancers being studied in the national PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) clinical trial.

Some of the major players operating in the market include: Qiagen, Abbott Laboratories Inc., Agilent Technologies, Merck Millipore, Biomerieux, Quest Diagnostics, F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., Thermo Fisher Scientific.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Cancer Biomarker Market
• 2.2. Research Methodology of the Cancer Biomarker Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL CANCER BIOMARKER MARKET COVID-19 IMPACT

6 GLOBAL CANCER BIOMARKER MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Protein
• 7.2. Genetic Biomarker
• 7.3. Glyco-Biomarkers

8 MARKET INSIGHTS BY INDICATION

• 8.1. Prostate Cancer
• 8.2. Breast Cancer
• 8.3. Lung Cancer
• 8.4. Colorectal Cancer
• 8.5. Cervical Cancer
• 8.6. Stomach Cancer
• 8.7. Liver Cancer
• 8.8. Others

9 MARKET INSIGHTS BY PROFILING TECHNOLOGIES

• 9.1. Omics Technologies
• 9.2. Imaging Technologies
• 9.3. Immunoassays
• 9.4. Bioinformatics
• 9.5. Cytogenetics

10 MARKET INSIGHTS BY APPLICATION

• 10.1. Drug Discovery & Development
• 10.2. Diagnostics
• 10.3. Prognostics
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. United States
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. France
  • 11.2.3. U.K.
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia Pacific
• 11.4. Rest of World

12 CANCER BIOMARKER MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 CANCER BIOMARKER MARKET OPPORTUNITIES

14 CANCER BIOMARKER MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 PRICE ANALYSIS

18 COMPETITIVE SCENARIO

• 18.1. Porter's Five Forces Analysis
• 18.2. Competitive Landscape

19 COMPANY PROFILED

• 19.1. Qiagen
• 19.2. Abbott Laboratories Inc.
• 19.3. Agilent Technologies
• 19.4. Merck Millipore
• 19.5. Biomerieux
• 19.6. Quest Diagnostics
• 19.7. F. Hoffmann-La Roche Ltd
• 19.8. Hologic Inc.
• 19.9. Illumina Inc.
• 19.10. Thermo Fisher Scientific

20 DISCLAIMER